Literature DB >> 17002548

Dissemination of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units of a medical center in Taiwan.

Tsu-Lan Wu1, Ju-Hsin Chia, Lin-Hui Su, Chishih Chu, An-Jing Kuo, Cheng-Hsun Chiu.   

Abstract

The prevalence of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a tertiary hospital in Taiwan was assessed over a 16-month period. A total of 125 nonrepetitive ESBL-producing isolates of Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae were available for investigation using molecular methods. Four predominant intensive care units (ICUs) were identified, and SHV-12 (59%), CTX-M- 3 (36%), and CTX-M-14 (14%) were the three most frequent ESBLs. SHV-12 was predominant among E. cloacae in the burn unit and K. pneumoniae in the other three chest medicine-related ICUs. CTX-M-3 was predominant among E. coli and K. pneumoniae in three other ICUs. The dissemination of ESBL-producing Enterobacteriaceae in four ICUs of a medical center in Taiwan is a consequence of the clonal dissemination of a few epidemic strains along with the horizontal transmission of resistance genes-carrying plasmids among bacterial organisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17002548     DOI: 10.1089/mdr.2006.12.203

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  2 in total

1.  Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy.

Authors:  Ching-Chi Lee; Nan-Yao Lee; Jing-Jou Yan; Hsin-Chun Lee; Po-Lin Chen; Chia-Ming Chang; Chi-Jung Wu; Nai-Ying Ko; Li-Rong Wang; Chih-Hsien Chi; Wen-Chien Ko
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Clinical and Molecular Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Klebsiella spp.: A Systematic Review and Meta-Analyses.

Authors:  Tirza C Hendrik; Anne F Voor In 't Holt; Margreet C Vos
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.